{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:07:26Z","timestamp":1789729646308,"version":"4.0.1"},"reference-count":76,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T00:00:00Z","timestamp":1160438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Most acute and chronic liver diseases are characterized by inflammatory processes with enhanced expression of various pro\u2010 and anti\u2010inflammatory cytokines in the liver. These cytokines are the driving force of many inflammatory liver disorders often resulting in fibrosis and cirrhosis.<\/jats:p><jats:p>Severe alcoholic hepatitis is a prototypic tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1)\u2010associated disease. This knowledge has recently led to pilot studies with promising results investigating specific anti\u2010TNF drugs such as infliximab or etanercept in the treatment of this disease, although a recently performed controlled French study did show a potential detrimental effect of this approach. Anti\u2010TNF treatment strategies might also improve chronic hepatitis C infection as shown by one controlled trial using etanercept administered subcutaneously for 24 weeks. Furthermore, several case reports suggest that TNF\u2010\u03b1 neutralization is not harmful to patients chronically infected with this virus. In contrast, neutralization of TNF\u2010\u03b1 worsens and might even be associated with fatalities in chronic hepatitis B infection. Anti\u2010inflammatory cytokines such as interleukin\u201010 (IL\u201010) have also been tried in patients with chronic liver diseases. Whereas IL\u201010 administered to patients with chronic hepatitis C virus infection shows indeed anti\u2010inflammatory effects in the liver, it seems to act as a proviral agent thereby limiting its clinical utility. Another cytokine with major anti\u2010inflammatory potential is the adipokine adiponectin, as its administration is beneficial in many experimental models of liver injury. Interference with cytokine pathways and\/or administration of anti\u2010inflammatory cytokines will be of major interest in the future therapy of many liver diseases.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2006.01339.x","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T19:07:02Z","timestamp":1160507222000},"page":"1029-1039","source":"Crossref","is-referenced-by-count":108,"title":["How to modulate inflammatory cytokines in liver diseases"],"prefix":"10.1111","volume":"26","author":[{"given":"Herbert","family":"Tilg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Moschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,10]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.09.110193.001533"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432007"},{"key":"e_1_2_8_5_2","first-page":"9248","article-title":"Mechanisms for virus\u2010induced liver disease","volume":"71","author":"Orange J S","year":"1997","journal-title":"tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391707"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.4.2247"},{"key":"e_1_2_8_8_2","first-page":"G579","article-title":"Antibodies to tumor necrosis factor\u2010alpha inhibit liver regeneration after partial hepatectomy","volume":"263","author":"Akerman P","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_8_9_2","first-page":"1577","article-title":"Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor","volume":"152","author":"Yamada Y","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5291.1379"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040605"},{"key":"e_1_2_8_12_2","first-page":"113","article-title":"Alcoholic liver disease","volume":"32","author":"Lieber C S.","year":"2000","journal-title":"new insights in pathogenesis lead to new treatments"},{"key":"e_1_2_8_13_2","first-page":"151","article-title":"Ethanol oxidizing enzymes","volume":"13","author":"Crabb D W.","year":"1995","journal-title":"roles in alcohol metabolism and alcoholic liver disease"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00427-0"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb04011.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007110"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-12-917"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840090302"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130211"},{"key":"e_1_2_8_20_2","first-page":"547","article-title":"Increased plasma interleukin\u20106 concentrations in alcoholic hepatitis","volume":"119","author":"Hill D B","year":"1992","journal-title":"J Lab Clin Med"},{"key":"e_1_2_8_21_2","first-page":"41","article-title":"Circulating and tissue levels of the neutrophil chemotaxin interleukin\u20108 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration","volume":"18","author":"Sheron N","year":"1993","journal-title":"Hepatology"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/33.6.606"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1990.tb00482.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90027-6"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.8.1182"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260621"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70354-9"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.7.4737"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(78)90401-8"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-9-685"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260802"},{"key":"e_1_2_8_32_2","first-page":"113","article-title":"Glucocorticoids are ineffective in alcoholic hepatitis","volume":"37","author":"Christensen E","year":"1995","journal-title":"a meta-analysis adjusting for confounding variables"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-4-299"},{"key":"e_1_2_8_34_2","first-page":"480","article-title":"Corticosteroids improve short\u2010term survival in patients with severe alcoholic hepatitis (AH)","volume":"36","author":"Mathurin P","year":"2002","journal-title":"individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH"},{"key":"e_1_2_8_35_2","first-page":"1637","article-title":"Pentoxifylline improves short\u2010term survival in severe acute alcoholic hepatitis","volume":"119","author":"Akriviadis E","year":"2000","journal-title":"a double-blind, placebo-controlled trial"},{"key":"e_1_2_8_36_2","first-page":"448","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis","volume":"37","author":"Spahr L","year":"2002","journal-title":"a randomized controlled pilot study"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00442-7"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20206"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04034.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.149.10.3339","article-title":"Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis","volume":"149","author":"Koziel M J","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655200453656"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.11.5283"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200102000-00016"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.11.1078"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20702"},{"key":"e_1_2_8_46_2","first-page":"580","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection","volume":"51","author":"Magliocco M A","year":"2004","journal-title":"report of 3 cases"},{"key":"e_1_2_8_47_2","first-page":"315","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment\u2010naive patients with chronic hepatitis C virus infection","volume":"42","author":"Zein N N.","year":"2005","journal-title":"a phase 2 randomized, double-blind, placebo-controlled study"},{"key":"e_1_2_8_48_2","first-page":"1","article-title":"TNF\u2010{alpha}, chronic hepatitis C and diabetes","volume":"98","author":"Knobler H","year":"2005","journal-title":"a novel triad"},{"key":"e_1_2_8_49_2","first-page":"840","article-title":"Hepatitis C virus infection and diabetes","volume":"126","author":"Shintani Y","year":"2004","journal-title":"direct involvement of the virus in the development of insulin resistance"},{"key":"e_1_2_8_50_2","first-page":"1384","article-title":"Impaired IRS\u20101\/PI3\u2010kinase signaling in patients with HCV","volume":"38","author":"Aytug S","year":"2003","journal-title":"a mechanism for increased prevalence of type 2 diabetes"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03179.x"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.686"},{"key":"e_1_2_8_53_2","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel M","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_54_2","first-page":"1363","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients","volume":"53","author":"Esteve M","year":"2004","journal-title":"need for primary prophylaxis"},{"key":"e_1_2_8_55_2","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan O","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21216"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031187"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60449-6"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80068-P"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.42"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.191"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240402"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840380412"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(00)00301-5"},{"key":"e_1_2_8_66_2","first-page":"84","article-title":"ACRP30\/adiponectin","volume":"13","author":"Berg A H","year":"2002","journal-title":"an adipokine regulating glucose and lipid metabolism"},{"key":"e_1_2_8_67_2","first-page":"46","article-title":"Beyond insulin resistance in NASH","volume":"40","author":"Hui J M","year":"2004","journal-title":"TNF-alpha or adiponectin?"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12255-6"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm724"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20282"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127953.98131.ED"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.02.130"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.145"},{"key":"e_1_2_8_74_2","first-page":"1779","article-title":"Adiponectin expression from human adipose tissue","volume":"52","author":"Kern P A","year":"2003","journal-title":"relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802594"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317797"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.08.029"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2006.01339.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2006.01339.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:23:58Z","timestamp":1695921838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2006.01339.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1478-3231.2006.01339.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01339.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}